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p53 induces cell death upon DNA damage, but this
may not confer all of its tumor suppressor activity.
We report thatp53activationenhances theprocessiv-
ity of DNA replication, as monitored by multi-label
fiber assays, whereas removal of p53 reduces fork
progression. This is observed in tumor-derived
U2OS cells but also in murine embryonic fibroblasts
with heterozygous or homozygous p53 deletion and
in freshly isolated thymocytes frommicewithdifferen-
tial p53 status. Mdm2, a p53-inducible gene product,
similarly supports DNA replication even in p53-defi-
cient cells, suggesting that sustained Mdm2-expres-
sion is at least one of the mechanisms allowing p53
to prevent replicative stress. Thus, p53 helps to pro-
tect the genome during S phase, by preventing the
occurrence of stalled or collapsed replication forks.
These results expand p53’s tumor-suppressive func-
tions, adding to the ex-post model (elimination of
damagedcells) an ex-ante activity; i.e., the prevention
of DNA damage during replication.
INTRODUCTION
No other gene is as frequently mutated across most tumor spe-
cies as TP53. Thus, p53must prevent tumor initiation and/or pro-
gression. Current concepts summarize the function of p53
largely as a mediator of cell death or permanent cell-cycle arrest
whenever cells suffer intolerable stresses, most notably when
DNA damage occurs. DNA damage induces the activation of
p53 as a transcription factor. Many of the p53-inducible genes
mediate apoptosis. This ensures the elimination of cells that
had suffered extensive DNA damage, conceivably avoiding the
accumulation of cells with heavily mutated DNA that might other-
wise give rise to malignant growth. Thus, the initial designation of
p53 as a ‘‘guardian of the genome’’ (Lane, 1992) only applies to a
whole organism, when damaged cells are eliminated to avoid
danger to the whole body. From the perspective of a single
cell, the ‘‘guardian’’ has a destructive role. According to currently
accepted models, p53 is acting largely ‘‘ex post’’ by destroyingCell Rep
This is an open access article unddamaged cells, but not ‘‘ex ante’’ to avoid DNA damage in the
first place. Although DNA repair has now become another well-
acknowledged activity promoted by p53 (Bieging et al., 2014),
this does still not imply that p53 actually prevents DNA damage,
rather than merely reacting to it.
However, some observations at least argue that p53 not only
eliminates cells with damaged DNA but exerts some of its tumor
suppressive activity by precluding such damage. Mice with a
constitutive deletion of p53 develop largely normally. At
4–6 months of age, however, tumors occur (Donehower et al.,
1992). In mice with switchable p53 alleles, p53 function can be
turned on and off at will, allowing the establishment of time win-
dows during which p53 is essential or dispensable for tumor sup-
pression (Martins et al., 2006). Using this system, established
lung tumors were only temporarily halted by reintroducing wild-
type p53 (Junttila et al., 2010), arguing that p53 may have a
more important role in preventing the formation of tumor cells
rather than destroying them ex post. Investigating mouse strains
with targeted deletions of key p53 target genes further chal-
lenged our current concept of p53-mediated tumor suppression.
Even when the major mediator of cell-cycle arrest, CDKN1A/
p21, and the key proapoptotic gene product, BBC3/Puma,
were both eliminated, p53 was still capable of suppressing
T cell lymphomas that otherwise occur almost without exception
when p53 itself is deleted (Valente et al., 2013). Similarly, an
acetylation-deficient p53 mutant that is largely unable to induce
cell-cycle arrest or apoptosis can still suppress T cell lym-
phomas in mice (Li et al., 2012). Thus, neither the proapoptotic
nor the cell-cycle regulatory function of p53 may be key to its
tumor suppressive activity.
In further support of a protective function of p53 toward indi-
vidual cells, the elimination of p53 does not always enhance
cell survival. Rather, removing p53 in the colon cancer-derived
cell line HCT116 increases the sensitivity of cells toward certain
chemotherapeutics, most notably doxorubicin and cisplatin
(Bunz et al., 1999). The sensitivity of p53-deficient cells toward
topoisomerase inhibitors was recently characterized in depth
by a drug screen and mechanistic analysis (Yeo et al., 2016).
Small interfering RNA (siRNA) screens revealed that the deple-
tion of some gene products decreases the viability of p53/
cells to a higher degree than their p53-proficient counterparts.
These genes are involved in nucleotide synthesis (e.g., UMPS)
(Bartz et al., 2006), DNA replication (e.g., Geminin) (Krastevorts 17, 1845–1857, November 8, 2016 ª 2016 The Authors. 1845
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Figure 1. p53-Mediated Induction of Genes during S Phase
(A) Thymidine block and release result in comparable cell-cycle distribution, independent of Nutlin pretreatment. U2OS cells were subjected to a double thymidine
block. Four hours before release from the block (or maintaining the block), 10 mM Nutlin (control: DMSO alone) was added. When the block was removed, the
previous concentration of Nutlin was maintained, followed by further incubation for 4 hr. The cellular DNA content was determined by propidium iodide staining
and flow cytometry.
(B) Nutlin induces comparable CDKN1A/p21 mRNA levels in proliferating cells, thymidine-arrested cells, and during S phase. U2OS cells were treated as in (A) or
grown asynchronously. Subsequently, CDKN1A/p21 mRNA (RT-PCR) and protein (Figure S1A; immunoblot analysis) levels were determined in triplicate (n = 2).
(C) RNA deep sequencing analysis reveals comparable induction of genes by Nutlin, in thymidine-block as well as during S phase. U2OS cells were treated as in
(A), followed by reverse transcription and next generation sequencing (Illumina). The heatmap reflects fold induction of the indicated genes by Nutlin according to
(legend continued on next page)
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et al., 2011), or DNA repair by homologous recombination (e.g.,
BRCA1 and RAD51) (Xie et al., 2012). Thus, p53may support cell
survival by preventing the accumulation of DNA damage during
challenges to DNA replication.
Our previous results indicate that p53 can protect cells toward
chemotherapeutics. These drugs still represent the mainstay of
cancer treatment (Dobbelstein andMoll, 2014), and the induction
of replicative stress is a keymechanismofmany chemotherapies
(Dobbelstein and Sørensen, 2015). When we activated p53 using
the pharmacological Mdm2 inhibitor Nutlin-3a (Nutlin) (Vassilev
et al., 2004), we observed decreased cytotoxicity of gemcitabine
(Kranz and Dobbelstein, 2006), UV-irradiation (Kranz et al.,
2008), and Wee1 inhibitors (Li et al., 2015). Initially, we ascribed
this mostly to the cell-cycle arrest function of p53, keeping the
cells out of S phase.
Here, we investigated whether p53 can influence the accumu-
lation of DNA damage and replicative stress during S phase.
However, previous reports suggested that p53 activity might
be attenuated during DNA replication. Most of these experi-
ments used hydroxyurea, an inhibitor of ribonucleotide reduc-
tase, to arrest the cells in S phase. Under such circumstances,
the induction of CDKN1A by p53 appeared reduced (Gottifredi
et al., 2001; Mattia et al., 2007). However, this does not exclude
an activity of p53 when cells proceed through S phase rather
than being arrested in it.
We show that p53 induces most of its target genes during
S phase and increases the processivity of DNA replication. The
absence of p53 causes replicative stress. This was observed
not only in tumor-derived cell lines, but in fibroblasts and thymo-
cytes from mice, comparing p53-proficient and p53-deficient
genotypes. Thus, p53 protects the genome by ensuring undis-
turbed progression of DNA replication forks.
RESULTS
p53 Is Capable of Inducing the Majority of Its Target
Genes during S Phase
Previous reports have suggested that p53 activity might be
attenuated while cells are replicating their DNA, but this was
mostly studied in the context of exogenous replicative stress
(Gottifredi et al., 2001; Mattia et al., 2007). To address this during
ongoing, unperturbed S phase, we synchronized U2OS cells us-
ing a double thymidine block (Bootsma et al., 1964; Xeros, 1962).
We then compared the expression of a bona fide p53 target
gene, CDKN1A/p21, between asynchronously proliferating cells,
cells that were arrested by a thymidine block, and cells that had
been released from the block to enter S phase. In each condition,
the cells were treated with the Mdm2-inhibitor Nutlin-3a (Nutlin)
to induce p53. Nutlin did not preclude the onset of S phase upon
release from the thymidine block (Figure 1A). We found that
CDKN1A/p21 mRNA levels were enhanced by Nutlin under all
three conditions but did not grossly differ between asynchro-
nous, arrested, and released cells (Figure 1B). When analyzingthe color scheme (color and blue line, log 2). Genes displaying an induction of >2
condition) in thymidine-blocked cells (Table S1) were included in the analysis. Mo
been released to enter S phase. The genes were sorted according to their p valu
heatmap) were inducible only in non-released cells but not in S phase.p21 protein levels by immunoblot, we observed the induction
by Nutlin under all three conditions again; p21 was even more
abundant in the cells that were released to enter S phase (Fig-
ure S1A). This argues against the view that p53 activity might
be impaired during DNA replication. To broaden this analysis,
we performed next-generation RNA sequencing to identify
Nutlin-inducible genes in thymidine-blocked versus released
cells. The induction of most p53-responsive genes was largely
unchanged regardless of the thymidine block. Less than ten
genes were no longer found induced by Nutlin when the cells
were allowed to proceed in S phase (Figures 1C and S1B; Table
S1). Thus, most capabilities of p53 to activate transcription are
preservedwhile cells replicate their DNA. Previous investigations
have mostly used hydroxyurea to arrest cells in S phase. Then,
the expression of p53-responsive genes was indeed found
attenuated (Gottifredi et al., 2001; Mattia et al., 2007). We pro-
pose that unperturbed S phase, but not an intra S phase arrest,
permit full p53 activity.
p53 Activation Enhances DNA Replication Processivity
Next, we asked whether p53 might exert a genome-protective
function during S phase by affecting DNA replication. U2OS cells
were first treated by Nutlin to induce p53 activity, as confirmed
by accumulation of p53 and its target gene products (Figure 2A).
Subsequently, the characteristics of DNA replication were as-
sessed by DNA fiber assays. The cells were sequentially incu-
bated with two different nucleoside analogs. Upon spreading
of the DNA on glass slides, we determined the length of DNA
tracks that were detected by antibodies due to incorporation
of the labels (Figure 2B).
Strikingly, the replication fork rate, indicating the distance that
a replication fork moves within a given amount of time, consis-
tently increased when the cells had been treated with Nutlin
before adding the labeling nucleosides (Figures 2C and 2D).
Notably, increased fork ratewasonly observedwhenNutlin treat-
ment was long enough to fully induce its target genes p21 and
Mdm2, while DNA replication still continued (Figures S2A–S2F).
We cannot exclude, however, that Nutlin may have shifted a ma-
jority ofDNA-replicating cells toward the lateSphase. Shortening
the incubation time with the second label IdU still allowed the
observation of an increased fork rate upon Nutlin treatment (Fig-
uresS2G–S2I). Conversely, the rate of origin firing, as determined
by a stretch of first label flanked by two stretches of second label,
was reduced upon Nutlin treatment (Figure 2E). This is in agree-
ment with the frequent observation that replication fork progres-
sion rate and origin firing are inversely correlated (Petermann
et al., 2010). However, interfering with origin firing by an inhibitor
ofCdc7, as described previously (Montagnoli et al., 2008), did not
compromise the increased fork progression rate in the presence
of Nutlin, whereas Cdc7 inhibition was itself sufficient to induce
p53 and to enhance the fork rate (Figures S3A–S3C). Thus, the
increased fork rate by p53 does not strongly depend on origin
firing. Counterstaining of the non-labeled fibers confirmed the-fold and a p value <0.05 (based on at least two independent samples for each
st of these genes were induced by p53 to a similar degree when the cells had
e identified in released cells. Only a small proportion of genes (bottom of the
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Figure 2. Enhanced Replication Fork Progression upon p53 Activation
(A) U2OS cells were treatedwith 8 mMNutlin or the DMSOsolvent for 14 hr and subjected to immunoblot analysis, detectingMdm2, p53, p21, and b-actin to reveal
the induction of p53 and its target gene products. A representative result of three biological replicates is shown.
(B U2OS cells were treated as described in (A) and further incubated with 5-chloro-20deoxy-uridine (CldU, 25 mM, 20 min) followed by iodo-deoxy-uridine (IdU,
250 mM, 120 min) as indicated, to label newly synthesized DNA.
(C) Tracks of newly synthesized DNA were visualized by immunostaining of CldU (red) and IdU (green).
(D) Fork progression was determined through the length of the second label (IdU; kb/min). Nutlin pretreatment caused a highly significant increase in the fork rate.
Note that fork progression is not identical to fork velocity, since shortening the observed track length can be a result of either slower replication or otherwise of
sudden fork stalling. In addition to the experiment shown here, two replicates are shown in Figure S2D.
(legend continued on next page)
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notion that the labeled track is part of a larger, intact DNA fiber
(Figure S3D). Taken together, the activation of p53 enhances
the ability of replication forks to move along the template DNA.
In principle, two phenomena can affect the movement of a
replication fork: (1) the speed by which the polymerases move
along the template might vary, and (2) the frequency that replica-
tion stalls can affect the outcome of a fiber assay when stalling
occurs during the period of DNA labeling (Figure S3E). To distin-
guish between these two possibilities, we modified the fiber
assay. We incubated the cells with two different nucleosides,
with repeated changes every 15 min (Figures 2F and 2G). In
this way, we distinguished the reasons for increased track length
upon p53 activation. Longer ‘‘stripes’’ containing one label
would indicate faster polymerization, whereas a higher rate of
fibers that contain all stripes with the two colors would indicate
less fork stalling (i.e., higher processivity). Upon induction of
p53 activity by Nutlin, we found a higher percentage of fibers
with the maximum number of labels (Figures 2H, 2I, and S3F;
Tables S2 and S3). In contrast, the length of the individual labels
2–5 did not significantly differ between the treatments with Nutlin
or DMSO alone (Figure 2J; Tables S2 and S3). Thus, activation of
p53 reduces the frequency of fork stalling and increases the
processivity of DNA replication.
p53 Depletion Hampers Replication Fork Progression
and So Does Mdm2 Depletion in a p53-Deficient
Background
We then sought to determine whether the depletion of p53 might
also modulate the ability of cells to replicate their DNA. First, we
depleted p53 from U2OS cells by siRNA. One set of cells was
also treated with gemcitabine, a nucleoside analog that induces
replicative stress by false incorporation and by inhibition of ribo-
nucleotide reductase. To assess the DNA damage response, we
determined the levels of phospho-H2AX by immunoblot anal-
ysis. As expected, gemcitabine induced the accumulation of
phospho-H2AX and also increased the levels of p53. Strikingly,
however, phospho-H2AX was further increased when p53 had
been knocked down (Figure 3A). We conclude that p53 depletion
augments the DNA damage response upon treatment with an
inducer of replicative stress.
To directly determine the impact of p53 depletion on DNA
replication, we performed fiber assays in the presence or
absence of gemcitabine (Figure 3B). In both cases, we observed
a significant decrease in replication fork progression (Figures 3C,(E) The proportion of first pulse origins, characterized by first label in the midd
determined. Nutlin-pretreated cells had a lower proportion of firing origins, in agre
tracks from five independent experiments is indicated below each box.
(F) Fiber assay to distinguish the speed of fork progression from the frequency of f
were subjected to one long first CldU label and then repeatedly incubated with I
(G) As a result of fiber staining, a long red track is followed by ‘‘stripes’’ that reflect
are reflected by fibers with less than seven labels.
(H) The number of forks that proceeded through n labels is displayed for DMSO-t
throughout the entire labeling time. Numbers lower than seven indicate that the
(I) The proportion of prematurely stalled forks (less than seven labels) indicates th
replication. Results from three independent experiments are summarized by them
determined for DMSO-treated or Nutlin-treated cells, and the relative decrease i
(J) Fork speed was determined through the length of labels two to five (kb/min).
impact on fork processivity (H and I).3D, and S4A–S4F). Thus, baseline levels of p53 carry out a pro-
tective function against replicative stress in U2OS cells.
The depletion of p53 did not detectably alter the cell-cycle dis-
tribution of U2OS cells (Figures S3G and S3H), and in contrast
with a previous report (Sablina et al., 2005), we did not observe
changes in the levels of mitochondrial reactive oxygen species
(ROS) upon depletion of p53 (Figure S4I). We then determined
whether p53 might affect fork regression upon stalling, as has
been reported in BRCA1-deficient cells (Ray Chaudhuri et al.,
2016). However, the interruption of DNA synthesis by transient
treatment with hydroxyurea (HU) (Figure 3E) after the first label
did not decrease the proportion of replication forks that pro-
ceeded to incorporate the second label, regardless of p53 deple-
tion (Figures S5A–S5C), nor did it shorten the track that was
labeled before HU addition (Figures S5D–S5H), as would have
been seen in the case of fork regression (Ray Chaudhuri et al.,
2016). However, the depletion of p53 decreased the speed of
fork progression after release from the HU block (Figures 3F,
3G, and S5I).
One of the most well-studied p53-responsive genes is Mdm2,
encoding a p53 antagonist. Indeed, even the baseline expres-
sion levels of Mdm2 were found to depend on p53 (Figure 3A).
We have recently reported an unexpected function of Mdm2
as a chromatin modifier (Wienken et al., 2016), raising the possi-
bility that Mdm2might affect DNA replication as well. To test this,
we depleted Mdm2 from cells and determined the DNA replica-
tion fork progression rate. However, knocking down Mdm2 in
p53-proficient cells would inevitably have led to robust and
long-term activation of p53. Therefore, we subjected a cell line
with a targeted deletion of p53 (Bunz et al., 1998) to siRNA trans-
fection, thus knocking down Mdm2 in a p53-deficient back-
ground (Figure S5J). Strikingly, the depletion of Mdm2 reduced
the fork rate of HCT116 p53/ cells and exacerbated gemcita-
bine-mediated replicative stress (Figures 3H–3J). The transcrip-
tion of known replicative stress response genes was not affected
by Mdm2 depletion (Figure S5K).This suggests that Mdm2 may
act as at least one mediator that allows p53 to protect DNA
replication, perhaps through its ability to modify histones and
chromatin structure (Wienken et al., 2016).
p53 Promotes the Progression of DNA Replication Forks
in Murine Embryonic Fibroblasts
To validate a possible influence of p53 onDNA replication in non-
transformed cells, we employed murine embryonic fibroblastsle flanked by second label at both sides, among all labeled structures was
ement with lower replicative stress. The number of evaluated fibers with labeled
ork discontinuation (processivity; Figure S3E). After treatment as in (A), the cells
dU and CldU for 15 min each.
CldU and IdU incorporation during the subsequent 15min pulses. Stalled forks
reated and Nutlin-treated cells. Seven labels reflect full progression of the fork
replication fork had discontinued during the labeling time.
at Nutlin-treatment reduced fork stalling and enhanced the processivity of DNA
ean and the SEM. In each experiment, the rate of prematurely stalled forks was
n this rate upon Nutlin treatment was calculated.
Nutlin treatment did not change the fork speed significantly, in contrast to its
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Figure 3. Increased Replicative Stress upon p53 Depletion and upon Depletion of Mdm2 from p53-Deficient Cells
(A) U2OS cells were treated with siRNA to knock down p53 or control siRNA for 48 hr, followed by treatment with 400 nM gemcitabine for 2 hr and immunoblot
analysis. Upon p53 knockdown, decreased amounts of Mdm2 and increased levels of phosphoH2AX (gH2AX) were observed. A representative result out of
greater than five replicates is shown.
(legend continued on next page)
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(MEFs). Wild-type MEFs were treated with Nutlin to induce p53
activity, followed by DNA fiber assays (Figure 4A). Strikingly, the
medianDNA replication fork ratewas increased 1.5-fold byNutlin
treatment, indicating that p53 is capable of strongly augmenting
the movement of DNA replication forks in these cells (Figures
4B and 4C). To test whether baseline p53 levels also affect fork
progression, we employed MEFs from mice with a conditional
p53 knockout (Jonkers et al., 2001). In these cells, the cre-recom-
binasecanbe inducedby4-hydroxy-tamoxifen (4-OHT).Wewere
comparing cells that contained wild-type p53 with cells that had
had been modified (‘‘floxed’’) by LoxP-insertions on both p53
alleles, as well as heterozygous cells, in the presence or absence
of gemcitabineWhen cells had been treatedwith 4-OHT to delete
the floxed alleles, we observed that replication fork progression
was severely impaired in MEFs with a homozygous p53 deletion
(Figures 4D–4F, S6A, and S6B). Similarly, the impact of gemcita-
bine on fork progression was aggravated by loss of p53, even in
MEFs where only one allele was lost by recombination (Figures
4G–4I and S6C). Some increase in the proportion of cells in
Sphasewasalsoobserved in cells that lack oneor twop53alleles
(Figures S6D and S6E). In sum, p53 supports DNA replication in
primary cells, and for this task, haploinsufficiency of the p53
gene was observed.
To assess the role of Mdm2 in DNA replication, we again used
a p53-deficient cell system to avoid p53 induction by loss of
mdm2. When comparing MEFs with a targeted deletion of p53
alone (single knockout) with cells that lack both p53 and mdm2
(double knockout) (Montes de Oca Luna et al., 1995), we
observed a marked decrease in DNA replication fork rate in
mdm2-deficient cells (Figures 4J–4L). Genes with relevance to
replicative stress were not found to be transcribed differentially
upon Mdm2 deletion (Figure S6F), based on our previous ana-
lyses (Wienken et al., 2016). In conclusion, and similar to
HCT116 p53/ cells (Figures 3H–3J), Mdm2 is required for effi-
cient DNA replication fork progression and may thus serve as a
mediator allowing p53 to enhance replication processivity.
p53 Increases DNA Replication Fork Processivity in
Murine Thymocytes before the Occurrence of T Cell
Lymphoma
Finally, we sought to test the impact of p53 on replication fork
progression under conditions that are as close as possible to a(B) Upon depletion of p53 (or control siRNA transfection), newly synthesized D
label only.
(C) DNA fibers were immunostained under the conditions described in (A) and (B
(D) Fork progression was determined through the length of the second label (Id
progression. This experiment was repeated as shown in Figure S4C.
(E) U2OS cells were treated with control and p53 siRNA for 48 hr, after which they
4 mM hydroxyurea (HU) for 2 hr to arrest replication forks. Upon release from the
were labeled with CldU and IdU without interrupting replication by HU.
(F) Labeled replication tracks were immunostained to visualize CldU (red) and Id
(G) Fork progression was determined through the track length corresponding to
replication forks. This effect was even more pronounced after an HU block. Sim
(H) HCT116 cells with a targeted deletion of p53 were transfected with siRNA to M
presence or absence of gemcitabine. Similar results were obtained with indepen
(I) Representative labeled tracks are shown as in in (C) and (F).
(J) Boxplot analysis of the fork rates, as determined by the tracks derived from t
Mdm2 depletion.living organism and in cells that are prone to cancer formation
in animals that lack p53. To this end, we employed thymocytes
freshly isolated from p53/ mice or their p53-proficient litter-
mates, at 4 weeks of age (i.e., at a time point prior to the occur-
rence of pre-cancerous cell clones) (Dudgeon et al., 2014).
Thymocytes from p53/ mice had a higher level of phosphor-
ylated H2AX than the corresponding p53+/+ cells (Figure 5A), at
least compatible with the view that the deletion of p53 leads to
enhanced replicative stress in vivo. This was not accompanied
by changes in mitochondrial ROS (Figure S7A). Of note, p53/
thymocytes showed a markedly impaired progression of DNA
replication forks, in the presence or absence of gemcitabine,
(Figures 5B–5E and S7B–S7G). We also determined the proc-
essivity of replication forks by frequent changes in the label
(Figures 5F–5J), an assay that we had first performed in
U2OS cells (Figures 2F–2J). When p53/ thymocytes were
repeatedly incubated with different labels of newly synthesized
DNA, it turned out that the number of stalled replication forks
increased in comparison to p53-proficient cells (Figure 5H,
summarized in Figure 5I). In contrast, the replication speed
observed in continuous tracks was not detectably affected by
the p53 status (Figure 5J), nor did we observe gross changes
in cell-cycle distribution (Figures S7H and S7I). Thus, p53 in-
creases the processivity of DNA replication in cells from the
thymus. We propose that the resulting replicative stress in
response to p53 loss might contribute to the occurrence of
chromosomal damage in these cells (Dudgeon et al., 2014), in
accordance with the formation of T cell lymphomas, observed
later in the lives of more than 90% of p53/ mice (Donehower
et al., 1992).
DISCUSSION
P53 is active during S phase, and it strengthens the processivity
of DNA replication. This was not only observed in p53-proficient
cancer cells but also in primary cells. Even thymocytes, the pre-
cursors of the most frequently found tumor species in p53/
mice, displayed impaired DNA replication. These observations
all support the view that p53 is not only acting ex post, by
eliminating or repairing cells that suffered DNA damage. Rather,
p53 appears to avoid replicative stress and associated damage
ex ante.NA was labeled with CldU and IdU. Gemcitabine was added during the IdU
).
U; kb/min). p53-depleted cells showed a highly significant reduction in fork
were labeled with 25 mMCldU for 20min. Subsequently, cells were treated with
HU block, the cells were labeled with 25 mM IdU for another hour. Control cells
U (green).
the second label (IdU). P53 depletion significantly reduced the progression of
ilar results to this experiment were found independently in Figure S5I.
dm2 or control siRNA. Subsequently, fork progression was determined in the
dent siRNAs to Mdm2 (not shown).
he second label, revealed reduced replication fork progression in response to
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Figure 4. p53-Supported DNA Replication in
Murine Embryonic Fibroblasts
(A) Wild-type murine embryonic fibroblasts (MEFs)
were treated with Nutlin or the DMSO control for
14 hr, followed by two-label fiber assays as indi-
cated.
(B) Fork progression was determined by immuno-
staining of CldU (red) and IdU (green).
(C) Thedegreeof fork progressionwas increasedby
Nutlinpretreatment, on ahighly significant level. The
indicated numbers of labeled fibers were evaluated
independently by two independent evaluators.
(D) MEFs with floxed p53 and a Cre-ERT2 fusion
gene driven by the ubiquitously active Rosa26
promoter were first treated with 4-hydroxy-
tamoxifen (4-OHT; 200 nM, 48 hr) to excise p53
exons 2–10 (Jonkers et al., 2001). Moreover,
ethanol was used as a solvent control to 4-OHT.
Subsequently, the cells were labeled with CldU
(25 mM, 20 min) and IdU (250 mM, 2 hr). In the
indicated experiments, 400 nM gemcitabine was
added to the second label.
(E) Labeled DNA tracks were immunostained to
detect CldU (red) and IdU (green).
(F) When comparing MEFs with two floxed p53
alleles before and after treatment with 4-OHT to
excise p53, a strong reduction in fork progression
was observed. This was true in otherwise untreated
cells and also upon treatment with gemcitabine. A
replicate of this experiment is shown in Figure S6B.
(G) Cells with two wild-type p53 alleles (wt/wt) and
with a mixed genotype (wt/fl) were investigated in
comparison with the fl/fl p53 genotype. 4-OHT
treatment was applied to excise p53 exons 2–10,
followed by labeling with CldU (25 mM, 20mins) and
IdU (25mM), in thepresenceof gemcitabine, for 2 hr.
(H) Labeled tracks of newly synthesized DNA were
stained with antibodies against CldU and IdU.
(I) Labeled track lengths were significantly reduced
upon removal of one or both p53 alleles. The result
was confirmed in Figure S6C.
(J) MEFs with a p53/ (single knockout) or a
p53/;mdm2/ (double knockout) genotypewere
incubatedwith theCldUand IdU labels as indicated,
followed by analysis of DNA fork progression. Note
that these MEFs are not directly comparable to the
preparations used in (A)–(I), due to differences in
passage numbers and genetic background, as
specified in the Experimental Procedures.
(K) Representative tracks are shown for each ge-
notype.
(L) Quantification of fiber lengths revealed that the
absence of mdm2, on the p53/ background, led
to a marked loss in replication fork progression.Our previous studies had already indicated that p53 activation
by Nutlin can protect p53-proficient cells from the cytotoxic ef-
fects of gemcitabine (Kranz and Dobbelstein, 2006) and also
from the combined effects of Wee1 inhibitors and gemcitabine
(Li et al., 2015). However, in those experiments, we had pre-
treated the cells with Nutlin for an extended period of time,
largely avoiding their entry into S phase. It appears obvious
that cells are resistant to replicative stressors when not in S.
Here, however, we show that p53 activity reaches far beyond
cell-cycle arrest to protect the cell against nucleoside analogs.1852 Cell Reports 17, 1845–1857, November 8, 2016Even under conditions where cells still undergo DNA replication,
p53 still exerts protection against replication fork stalling.
The vast majority of mice that lack p53 will develop T cell lym-
phoma at 6 months of age (Donehower et al., 1992). Deep
sequencing analysis revealed that the first clones with rear-
ranged DNA become detectable at 9 weeks after birth (Dudgeon
et al., 2014). Our results show that replicative stress occurs in
the bulk of thymocytes even earlier, i.e., at 4 weeks of age.
This strongly argues that replicative stress precedes the occur-
rence of detectable premalignant cell clones in p53/mice. It is
Figure 5. Replicative Stress in Murine Thy-
mocytes Lacking p53
(A) Immunoblot analysis revealing enhanced H2AX
phosphorylation in p53/ thymocytes. Freshly
isolated thymocytes from mice with the indicated
genotype were subjected to immunoblot analysis
to detect p53 and phospho-Ser139 histone 2A
(gH2AX). Total protein staining by Ponceau S
served as a loading control.
(B) Thymocytes were subjected to fiber assays
immediately after their isolation from 4-week-old
mice with different p53 status (homozygous
knockout, heterozygous, or wild-type). The label-
ing (CldU and IdU, 25 mM each) was performed in
the presence or absence of 100 nM gemcitabine.
(C) Labeled DNA tracks were immunostained to
visualize incorporated CldU (red) and IdU (green).
(D and E) Fork progression was assessed by the
length of the IdU fibers and displayed by boxplots.
Decreased fork progression was observed in ho-
mozygous knockout cells, at a highly significant
level, in untreated cells (D) and in gemcitabine-
treated thymocytes (E) (confirmation in Figures
S7C and S7D).
(F) To determine fork processivity, multiple labels
were performed as in Figures 2F–2J, with a total of
five labels.
(G) Immunostaining allowed the clear distinction of
up to five CldU/IdU-labeled tracks.
(H) The number of prematurely stalled replication
forks (less than five labels) was found increased in
thymocytes from p53/ mice, compared to cells
from p53-proficient mice.
(I) The proportion of prematurely stalled replication
forks was significantly increased in p53-deficient
thymocytes. Results from three independent ex-
periments are summarized by the mean and the
SEM. In each experiment, the rate of prematurely
stalled forks was determined for cells from mice
with a p53+/+, p53+/, and p53/ genotype, and
the relative decrease in this rate depending on the
deletion of the p53 alleles was calculated.
(J) As observed in U2OS cells (Figure 2J), the
replication speeds observed in single tracks, here
determined by labels two through four, were
unchanged.at least conceivable that replicative stress in thymocytes plays a
causal role for tumor formation. In such a scenario, the attenu-
ation of replicative stress would represent an essential part of
the tumor suppressive activity of p53. Accordingly, it is note-
worthy that even the triple deletion of the p53 target genes
cdkn1a, pmaip1/noxa, and bbc3/puma does not recapitulate
the phenotype of p53 null mice. The triple deletions do not
give rise to T cell lymphoma or other cancers (Valente et al.,
2013). Rather, p53 target genes that support DNA replication
(e.g., mdm2) might represent mediators of tumor suppression
in vivo.
It would be tempting to speculate that p53 can support DNA
replication by physical association with the replication fork. It
has long been noticed that p53 is capable of interacting withinsertion/deletion mismatches that may form during replication
(Lee et al., 1995) and with the ‘‘chickenfoot’’ structure at re-
tracted replication forks (Subramanian and Griffith, 2005)
in vitro. However, in our hands, no visible fork regression was
found when depleting p53 (Figures S5D and S5H), and the accu-
mulation of p53 only affected DNA replication fork progression if
it had lasted for half a day (Figures 2A–2D and S2A–S2F), an
amount of time required to enhance the mRNA levels corre-
sponding to most p53 target genes (Zhao et al., 2000). While
not excluding transcription-independent contributions of p53
(e.g., by suppressing excessive homologous recombination)
(Arias-Lopez et al., 2006; Bertrand et al., 2004; Janz and
Wiesm€uller, 2002), we propose that p53-target genes are at least
necessary for the impact of p53 on DNA replication. Indeed, oneCell Reports 17, 1845–1857, November 8, 2016 1853
of the genes with the strongest p53-inducibility, Mdm2, was
found to facilitate DNA replication independent of its ability to
antagonize p53 (Figures 3H–3J and 4J–4L). Interestingly, as we
have shown recently (Wienken et al., 2016), Mdm2 acts as a
chromatin modifier, and chromatin modifications are capable
of interfering with DNA replication in multiple ways (Alabert and
Groth, 2012). However, Mdm2 is also capable of binding Nbs1
(Bouska et al., 2008), raising the possibility that it might support
the functions of the MRN complex in resolving replication inter-
mediates (Bruhn et al., 2014) or in activating ATR-Chk1-signaling
(Duursma et al., 2013). The anti-oxidative activity of Mdm2 (Ris-
cal et al., 2016) may also contribute to smooth DNA replication,
although we have not observed increased ROS upon removal of
p53 (Figures S4I and S7A). Curiously, Mdm2 was also reported
to enhance replicative stress when overexpressed (Frum et al.,
2014). However, transgenic overexpression of Mdm2 has long
been known to yield paradoxical growth arrest rather than its
physiological oncogenic function (Brown et al., 1998), and similar
effects might be responsible for the observed replication stress
in overexpression systems. In our study, we thus avoided
Mdm2 transgenes, and all observations were made by exploring
Mdm2 from an endogenous source.
Perhaps similarly, a recent report described the deceleration
of replication fork progression as a response to p53 activity
(Hampp et al., 2016), in seeming contrast with our observations
and with another report on a role for p53 in avoiding conflicts of
transcription and replication (Yeo et al., 2016). However, the ma-
jority of the experiments reported by Hampp et al. (2016) were
carried out using transgenic overexpression of p53, which might
well have led to non-physiological situations, or in cell systems
other than those described in our study. In contrast, we have
performed our assays in the very same cells from p53-deficient
animals that give rise to cancer later in life (i.e., thymocytes) (Fig-
ure 5). There, endogenous wild-type p53 contributed to DNA
replication with greater processivity than in p53-deficient thymo-
cytes. Therefore, we propose that in a cancer-relevant system,
p53 acts to protect DNA replication forks against stalling and
collapse, thus preserving the genome during this highly vulner-
able phase.
On top of Mdm2, additional p53 target genes might be
involved in the p53-driven support of DNA replication. Candi-
dates include the ribonucleotide reductase p53R2, capable of
increasing the available dNTP pool (Nakano et al., 2000; Tanaka
et al., 2000). Similarly, the p53-inducible lncRNA NEAT1
dampens replicative stress through paraspeckle formation and
ATR activation (Adriaens et al., 2016). On the other hand, the
p53-inducible gene product p21/CDKN1A was reported to
enhance rather than inhibit replicative stress, at least under cir-
cumstances that involve UV irradiation (Mansilla et al., 2013) or
senescence (Galanos et al., 2016). Thus, the impact of p53 on
DNA replication may also depend on the exogenous stressors
and the cell-specific set of p53-responsive genes.
The relatively long time periods of labeling replicating DNA
used in many of our experiments might conceivably have led
to the collision of forks, considering average replication origin
distances (Conti et al., 2007; Lebofsky et al., 2006). However,
we rarely observed such collisions, perhaps pointing to different
replication origin distances between cell species and also to the1854 Cell Reports 17, 1845–1857, November 8, 2016slower progression of replication forks between closely situated
origins (Conti et al., 2007).
How could replicative stress lead to cancer? In addition to
nucleotide misincorporations, cells with incompletely replicated
DNA might enter irregular mitosis, giving rise to chromosomal
instability. In agreement, sites of replicative stress often coincide
with common fragile sites (i.e., breakpoints of chromosome rear-
rangements) (Glover et al., 2005). The removal of p53 strongly
compromises the G2-M checkpoint that normally prevents the
onset of mitosis when DNA is damaged or incompletely repli-
cated (Taylor et al., 1999). Thus, p53 may prevent the accumula-
tion of chromosomal rearrangements by avoiding fork stalling
and also premature mitosis. In support of this model, the thymo-
cytes in p53/mice accumulate chromosomal rearrangements,
and even chromotrypsis, at ages before full-blown T cell lym-
phomas arise (Dudgeon et al., 2014).
At least in MEFs, even a heterozygous p53 deletion was
capable of increasing replicative stress (Figure 4). This is similar
to the situation in patients suffering from Li-Fraumeni syndrome.
There, all somatic cells carry one allele with a p53 mutation and
another allele with an intact TP53 gene. So far, the occurrence of
cancer in these patients was mostly ascribed to a loss of hetero-
zygosity. In contrast, our results suggest that even the heterozy-
gous situation may increase replicative stress at least in some
cell species and thus enhance the probability of mutations or
chromosomal rearrangements. Thus, a subset of cells in such
patients may be cancer-prone even before the intact allele of
p53 is lost.
Approximately 50% of all humanmalignant tumors carry a p53
mutation. However, tumor progression studies such as those on
colorectal cancer revealed that, in general, p53 undergoesmuta-
tions late during tumor development (Fearon and Vogelstein,
1990). One reason for this phenomenon might be that the pres-
ence of p53, through its ability to ensure unperturbed DNA repli-
cation, can support the initial survival of cancer cells. Only at late
stages, the tumor cell might be able to tolerate the loss of p53
and the concomitant replicative stress. It might then take advan-
tage of the enhanced genomic variability and the consequent
ability of adaptation (e.g., during invasion and metastasis).
Our results also point to a selective vulnerability of p53-defi-
cient cells toward chemotherapeutics that enhance replicative
stress. Indeed, enhanced sensitivity of p53/ cells toward
selected chemotherapeutics was described more than 15 years
ago (Bunz et al., 1999). Recently, this phenomenonwas ascribed
to an ability of p53 to prevent interference between transcription
andDNA replication that would otherwise require topoisomerase
activity to be resolved (Yeo et al., 2016). Here, we identify p53 as
a supporter of DNA replication processivity in primary cells that
undergo tumor formation when p53 is deleted.
P53 has long been known as a guardian of the genome. How-
ever, most of these protective functions appeared retroactive
from the point of a single cell, as if a guardian killed his injured
master after an attack. Here, however, we identify a proactive
way of how p53 prevents DNA damage even before it occurs.EXPERIMENTAL PROCEDURES
The Supplemental Experimental Procedures are available online.
Cell Culture, siRNA Transfections, and Treatment
U2OS (Osteosarcoma, p53 wild-type) cells were transfected with Lipofect-
amine 2000, synchronized with a double 2mM thymidine block, and/or treated
with Nutlin-3a (Sigma, N6287), gemcitabine (Eli Lilly), and hydroxyurea (Sigma-
Aldrich, H8627) as indicated.
Mouse embryonic fibroblasts (MEFs) were isolated from p53loxP mice
(Jonkers et al., 2001) (B6.129P2-Trp53tm1Brn/J, Jackson Laboratories)
at E13.5. Littermates were used to prepare MEFs from a C57Bl6N/129SV
background (50%–50%, N2 Backcross). MEFs from p53/ and from
p53/;mdm2/ mice were obtained from Y. Zhang, University of North Car-
olina (Itahana et al., 2007; Wienken et al., 2016).
Thymocytes were isolated from 4-week-old Trp53tm1Tyj mice (Jackson
Laboratories), carrying a deletion of the p53-encoding gene (Jacks et al.,
1994). The thymus was isolated and strained through a 40 mM mesh. Cells
were used for experiments immediately thereafter.
Fiber Assays
DNA fiber assays to analyze replication fork progression and origin firing were
essentially carried out as described previously (Ko¨pper et al., 2013). For two-
label assays, the cells were incubated with 5-chloro-20-deoxyuridine (CldU) for
20 min, followed by 5-iodo-20-deoxyuridine (IdU; both from Sigma-Aldrich) for
20 min, 1, or 2 hr, accompanied by treatment with gemcitabine or inhibitors as
indicated. For multiple label assays, cells were pulse labeled with CldU for 1 hr,
followed by alternate labels of IdU and CldU.
DNA fibers were spread on glass slides as described (Ko¨pper et al., 2013).
After acid treatment, CldU- and IdU-labeled tracts were detected by 1 hr incu-
bation at 20C with rat anti-BrdU antibody (dilution 1:500 detects BrdU and
CldU; AbD Serotec) and mouse anti-BrdU antibody (1:200–1:500, detects
BrdU and IdU; Becton Dickinson). Slides were fixed in 4% paraformalde-
hyde/PBS and incubated for 2 hr at 20C with Alexa Fluor 555-conjugated
goat anti-rat antibody (dilution 1:150–250) or Alexa Fluor 488-conjugated
goat anti-mouse antibody (dilution 1:100–1:250; both from Molecular
Probes/Thermo Fisher). In some cases, counterstaining was performed with
an antibody to single-stranded DNA (Millipore, #MAB 3034) and an
Alexa647-coupled secondary antibody. Fiber images were acquired by fluo-
rescence microscopy.
Statistical Testing
Statistical testing was performed using Graph Pad Prism 6. A two-sided un-
paired t test was calculated with an assumed significance for p values %
5%. The term ‘‘n.s.’’ indicates that no significant difference was found.
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